Delivery Order HHSO100201300006I-75A50118F33003
- This is a $999,406,548.42 firm fixed price definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Amgen USA Inc., a leading biotechnology company. The contract is for the treatment of thrombocytopenia or platelet loss in a mass casualty event, with the procured therapeutic to be delivered to the Strategic National Stockpile as vendor managed inventory. The contract exercises option periods 3 for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Neupogen 480 mcg/1.6 mL vials, with a ceiling value of $1,934.37. This competitively awarded, non-set-aside order was placed on August 17, 2025, with an ultimate completion date of August 18, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract utilizes firm fixed-price pricing terms. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $27,011.21 to AmerisourceBergen Drug Corp for the supply of Neulasta OnPro 6 mg/0.6 ml kits on August 29, 2025, with completion scheduled for September 2, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's broader relationship with the federal government. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a $3,505.98 delivery order to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL kits, with an ultimate completion date of June 3, 2025. This non-set-aside, firm fixed-price contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under the company's broader pharmaceutical supply agreement with the federal government. This...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the Amerisourcebergen Corporation, to provide GONAL-F RFF REDI-JECT 900 UNIT 1.5ML pharmaceutical products. The delivery order has a potential value of $2,449.30 and a completion date of January 30, 2024. Amerisourcebergen Drug Corp, as the prime contractor, is a for-profit organization that serves as a supplier of pharmaceuticals,...
- This contract awarded to Amgen Inc. by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) provides $33,719,968.24 to advance the development of romiplostim for the treatment of hematopoietic subsyndrome-acute radiation syndrome (HS-ARS) and chemotherapy-induced thrombocytopenia (CIT), as well as a drug delivery device feasibility project. The contract includes a $3,711,014.00 supplement to CLIN 002 and the de-obligation of...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $17,831.39, is for the delivery of NEULASTA ONPRO 6 MG/0.6 ML KIT 0.6ML, a specialty medication. This contract does not have a set-aside designation, indicating it was competed openly. AmerisourceBergen is the prime contractor, and the contract has an ultimate completion date of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,530.76 to AmerisourceBergen Drug Corp for Neulasta Onpro 6 mg/0.6 ml kits on September 9, 2025, with completion scheduled for September 10, 2025. The award utilized firm fixed pricing with no set-aside designation, indicating competitive selection among eligible contractors. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate...
- This is a delivery order under a larger Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp. The delivery order is for the pharmaceutical product GONAL-F RFF REDI-JECT 450 UNIT 0.75ML, with a ceiling value of $3,622.06 and a performance period through July 2024. The IDC held by Amerisourcebergen with DLA Troop Support Medical is valued at $999,999,999 and covers a wide range of pharmaceutical...
- The Defense Logistics Agency awarded a $21,950 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GONAL-F RFF Redi-Ject 900 Unit 1.44ML, a pharmaceutical product used in fertility treatment. The award was made on September 11, 2025, with an ultimate completion date of September 12, 2025, and is not designated as a set-aside contract. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- HHS Colony Stimulating Factor 2013-2018Master IDIQ
- HHSO100201300006IIndefinite Delivery Contract
- HHSO100201300006I-75A50118F33003Delivery Order
This firm fixed price delivery order was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response against the HHS Colony Stimulating Factor 2013-2018 master indefinite delivery indefinite quantity contract. Valued at $708,420.30, the order is for maintenance of previously purchased colony stimulating factor(s), specifically G- or GM-CSF, for mitigation of neutropenia arising from exposure to ionizing radiation. The products will be delivered through March 2024 in support of the agency's acquisition of these medical countermeasures. Amgen USA Inc. will serve as the prime contractor, providing the colony stimulating factors from its location in Thousand Oaks, California. No set-aside designation was applied to this award.
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Acquisition of Colony Stimulating Factor(s) (G-CSF or GM-CSF) for mitigation of Neutropenia arising from exposure to ionizing radiation | RFP-12-100-SOL-00016 | Department of Health and Human Services Immediate Office of the Secretary | Award Notice 3/3 | 9/30/16, 2:40 PM | |
Acquisition of Colony Stimulating Factor(s) (G-CSF or GM-CSF) for mitigation of Neutropenia arising from exposure to ionizing radiation | RFP-12-100-SOL-00016 | Department of Health and Human Services Immediate Office of the Secretary | Award Notice 2/3 | 9/30/16, 2:38 PM | |
Acquisition and Advanced Development of a Colony Stimulating Factor (G- or GM-CSF) for mitigation of neutropenia arising from exposure to ionizing radiation | RFP-12-100-SOL-00016 | Department of Health and Human Services Immediate Office of the Secretary | Award Notice 1/3 | 6/25/12, 9:44 AM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00003 | Other Administrative Action | $0 | 1/12/24 | |
| P00002 | Other Administrative Action | $66.3k | 9/7/23 | |
| P00001 | Exercise an Option | $49.1k | 9/13/21 | |
| Not listed | Not listed | $542.0k | 8/20/18 |